In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Michael W. Magdycz
Advertisement
Articles by Michael W. Magdycz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
3
FDA’s Shift Signals a New Era for Data-Driven Drug Development
4
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
5